<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>1481554</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.1186/1471-2393-6-10</infon><infon key="article-id_pmc">1481554</infon><infon key="article-id_pmid">16595003</infon><infon key="article-id_publisher-id">1471-2393-6-10</infon><infon key="fpage">10</infon><infon key="journal-title">BMC Pregnancy and Childbirth</infon><infon key="license">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</infon><infon key="lpage">10</infon><infon key="name_0">surname:Ahn;given-names:Eric</infon><infon key="name_1">surname:Pairaudeau;given-names:Nicholas</infon><infon key="name_2">surname:Pairaudeau;given-names:Nicholas;suffix:Jr</infon><infon key="name_3">surname:CÃ©rat;given-names:Yves</infon><infon key="name_4">surname:Couturier;given-names:Bernard</infon><infon key="name_5">surname:Fortier;given-names:Andre</infon><infon key="name_6">surname:Paradis;given-names:Ãric</infon><infon key="name_7">surname:Koren;given-names:Gideon</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">6</infon><infon key="year">2006</infon><offset>0</offset><text>A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>198</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>209</offset><text>Prenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms. This coupled with nausea and vomiting of pregnancy results in women often discontinuing their multivitamins.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>438</offset><text>A new prescription supplement (PregVitÂ®) that separates iron from calcium in two tablets â morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (MaternaÂ®). The objectives of this study were to compare tolerability and compliance with PregVitÂ® vs. a supplement with high iron content (MaternaÂ®), in pregnant women.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>890</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>898</offset><text>Randomized, crossover open labeled study in 135 pregnant women attending outpatient clinics in Ontario and Quebec.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1013</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1021</offset><text>Use of PregVitÂ® was associated with a 30% reduction in constipation rate as compared to MaternaÂ®. Both products demonstrated similar compliance rates.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1174</offset><text>Compliance of MaternaÂ® was negatively associated with the severity of nausea and vomiting of pregnancy. No such correlation was found for PregVvitÂ®.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1325</offset><text>Conclusion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1336</offset><text>PregVitÂ®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates. High iron content in multivitamin supplements is associated with adverse effects in pregnancy.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1604</offset><text>Background</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1615</offset><text>Prenatal micronutrient supplementation is indicated for all pregnant women, because the recommended daily allowances (RDA) for many vitamins and minerals are not met during pregnancy with dietary sources alone. Prior to 1990's, physicians typically commenced prenatal micronutrients at the time of diagnosis of pregnancy. However, proving the ability of folic acid supplementation to prevent neural tube defects, has led to the recommendation to start prenatal micronutrient supplementation when planning pregnancy. A recent analysis has further documented the importance of micronutrient supplementation during pregnancy in preventing malformations other than neural tube defects. The findings are consistent with the notion that periconceptional multivitamin use, containing folic acid, reduces the overall occurrence of birth defects by 15â33%, in addition to the demonstrated reduction in neural tube defects.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2531</offset><text>Typically, many prenatal supplements contain, among other minerals, elemental iron at 50â60 mg, to prevent pregnancy-induced anemia secondary to increasing fetal needs. However, this level of iron content has been associated adverse gastrointestinal effects, including nausea, vomiting and constipation. The common occurrence of nausea and vomiting of pregnancy (NVP) has further led women to discontinue prenatal supplementation containing these levels of iron.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2996</offset><text>A new prescription prenatal micronutrient supplement PregVitÂ® has recently been introduced into the Canadian Market aiming to address these issues: PregVitÂ®, taken twice daily, contains less elemental iron (35 mg) than many other prenatal supplements. Iron is incorporated in the morning dose (Table 1). The evening dose of PregVitÂ® contains calcium, which is known to inhibit iron absorption from the gastrointestinal tract. By separating the two elements it was hypothesized that despite a lower total iron dose â a similar systemic exposure to iron would occur as with the other high iron prenatal supplements. Moreover, PregVitÂ® contains higher doses of vitamin C, which is also known to facilitate iron absorption (Table 1).</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>3732</offset><text>Composition of two prenatal supplements and Recommended Dietary Allowance (RDA) values12</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Component&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;PregVit&lt;/bold&gt;&lt;sup&gt;Â®&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Materna&lt;/bold&gt;&lt;sup&gt;Â® &lt;/sup&gt;***&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Recommended dietary allowance (RDA)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;a.m. tablet**&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vit. A&lt;sup&gt;Ï&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;2700 IU (Î²-Carotene)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1500 IU (Î²-Carotene) 1500 IU (acetate)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;750â770 Î¼g retinol&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vit. E&lt;sup&gt;Î¾&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;30 IU&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;30 IU&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;15 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vit. C&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;120 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;100 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;80â85 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vit. B&lt;sub&gt;1 &lt;/sub&gt;(thiamin)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;3 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;3 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1.4 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vit. B&lt;sub&gt;2 &lt;/sub&gt;(riboflavin)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;3.4 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;3.4 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1.4 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Niacinamide&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;20 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;20 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;18 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vit. B&lt;sub&gt;6&lt;/sub&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;10 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;10 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1.9 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Pantothenic acid (calcium pantothenate)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;5 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;10 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;6 mg*&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Magnesium&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;50 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;50 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;350â400 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Iodine&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0.15 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0.15 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0.22 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Iron&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;35 mg (as fumarate)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;60 mg (as fumarate)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;27 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Copper&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;2 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;2 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Zinc&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;15 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;25 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;11â12 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;p.m. tablet**&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Folic Acid&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1.1 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0.6 mg&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vit. B&lt;sub&gt;12 &lt;/sub&gt;(cyanocaobalamin)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;12 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;12 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;2.6 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vit. D (cholecalciferol)&lt;sup&gt;Îµ&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;250 IU&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;250 IU&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;5 Î¼g*&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Calcium&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;300 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;250 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1000â1300 mg*&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Biotin&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;30 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Chromium&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;25 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;29â30 Î¼g*&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Manganese&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;5 mg&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;2 mg*&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Molybdenum&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;25 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;50 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Selenium&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;25 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;60 Î¼g&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Pill Size&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Small&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;large&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>3821</offset><text>Component	PregVitÂ®	MaternaÂ® ***	Recommended dietary allowance (RDA)	 		a.m. tablet**			 	Vit. AÏ	2700 IU (Î²-Carotene)	1500 IU (Î²-Carotene) 1500 IU (acetate)	750â770 Î¼g retinol	 	Vit. EÎ¾	30 IU	30 IU	15 mg	 	Vit. C	120 mg	100 mg	80â85 mg	 	Vit. B1 (thiamin)	3 mg	3 mg	1.4 mg	 	Vit. B2 (riboflavin)	3.4 mg	3.4 mg	1.4 mg	 	Niacinamide	20 mg	20 mg	18 mg	 	Vit. B6	10 mg	10 mg	1.9 mg	 	Pantothenic acid (calcium pantothenate)	5 mg	10 mg	6 mg*	 	Magnesium	50 mg	50 mg	350â400 mg	 	Iodine	0.15 mg	0.15 mg	0.22 mg	 	Iron	35 mg (as fumarate)	60 mg (as fumarate)	27 mg	 	Copper	2 mg	2 mg	1 mg	 	Zinc	15 mg	25 mg	11â12 mg	 		p.m. tablet**			 	Folic Acid	1.1 mg	1 mg	0.6 mg	 	Vit. B12 (cyanocaobalamin)	12 Î¼g	12 Î¼g	2.6 Î¼g	 	Vit. D (cholecalciferol)Îµ	250 IU	250 IU	5 Î¼g*	 	Calcium	300 mg	250 mg	1000â1300 mg*	 	Biotin	0	30 Î¼g	-	 	Chromium	0	25 Î¼g	29â30 Î¼g*	 	Manganese	0	5 mg	2 mg*	 	Molybdenum	0	25 Î¼g	50 Î¼g	 	Selenium	0	25 Î¼g	60 Î¼g	 	Pill Size	Small	large		 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>4800</offset><text>* Adequate Intake</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>4818</offset><text>** Applies only to PregVitÂ®</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>4847</offset><text>ÏVIT A â 1 International Unit (IU) of retinol is equivalent to 0.3 Î¼g retinol (750 Î¼g of retinol is 2,500 IU of retinol)</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>4973</offset><text>2 Î¼g of supplemental Î²-carotene is equivalent to 1 Î¼g retinol 3 (page 92 &amp; 565)</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>5058</offset><text>Î¾VIT E â 1 International Unite (IU) is equivalent to 0.67 Î¼g of Î±-tocopherol (15 mg is equivalent to 22,388 IU)</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>5176</offset><text>However, different conversion factors are used for different forms of vitamin E</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>5256</offset><text>ÎµVIT D â 1 IU is equivalent to 0.025 Î¼g of cholecalciferol (5 Î¼g is equivalent to 200 IU)</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>5354</offset><text>***Please note: Since the completion of this study a new formulation of Materna was introduced containing 27 mg of elemental iron.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5485</offset><text>A recent pharmacokinetic study has shown that the extent of iron absorption with PregVitÂ® (in terms of area under the concentration-time curve) was similar to that of MaternaÂ®, despite PregVitÂ®containing only about half of the iron dose.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5726</offset><text>The objective of the present study was to compare tolerability and compliance with PregVitÂ® and MaternaÂ® among pregnant women.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5855</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5863</offset><text>Approval of the study protocol was obtained from the local ethics committee at The Hospital for Sick Children, in Toronto, Ontario, the North York General Hospital (NYGH) in Toronto, Ontario and the Clinique de GynÃ©cologie-ObstÃ©trique Pierre Boucher (CGOPB) in Quebec. Appropriate sample size was determined to be one hundred participants based on a desired effect size of 20% fewer adverse effects with PregVitÂ® versus MaternaÂ®.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6297</offset><text>Participants were eligible to enroll in the study if they were pregnant and between 18 and 45 years of age. This was a prospective, randomized, open labeled, cross over study. Between June 2003 and November 2003, women attending out patients obstetric clinics at NYGH and CGOPB were invited to enroll in the study. During their regular first obstetric appointment, participants reviewed the protocol and signed an informed consent form. Participating women were asked to complete a standardized questionnaire recording demographic data, pregnancy and, medical history, drug and vitamin use and information on their normal bowel movements. Based on the existence of NVP, participants were block-randomized to receive either MaternaÂ® or PregVitÂ® to be taken for one month. The block randomization aimed at ensuring similar numbers of women with NVP/no NVP receiving each of the products first as NVP may affect compliance. They were asked to keep a diary of any adverse event (e.g. constipation, nausea and headache). The severity of their NVP was monitored by the Pregnancy-Unique Questionnaire of Emesis and nausea (PUQE) scores (Table 2). In addition, changes in diet as well as the use of medications and adherence to the study drug were recorded in the diary. At the end of the month a pill count was conducted to corroborate their diary reports. One month later, upon their regular second follow-up visit, patients returned their diaries and pill bottles. The women were then given the alternative product and were asked to record the same information in the diary for the following month. Upon completion of the two month cross over, participants were asked to return their diaries and supplement bottles for a pill count.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>8027</offset><text>The PUQE Score (12). Patients were asked to circle the appropriate box next to the three symptoms of nausea and vomiting of pregnancy (NVP). The score of each box is represented by the top row. The total score is calculated and determines the severity of NVP14. A score of 3 to 6 represents Mild NVP. A score of 7 to 12 indicates Moderate NVP. Finally a score of 13 and greater represents Severe NVP.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;1&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;2&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;3&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;4&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;5&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;&lt;italic&gt;&lt;underline&gt;QUESTION 1&lt;/underline&gt;&lt;/italic&gt;&lt;/bold&gt;In the last 12 hours, how long have you felt &lt;bold&gt;nauseated or sick at your stomach&lt;/bold&gt;?&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Not at all&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1 hour or less&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2â3 hours&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;4â6 hours&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;More than 6 hours (Please specify number of hours)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;&lt;italic&gt;&lt;underline&gt;QUESTION 2&lt;/underline&gt;&lt;/italic&gt;&lt;/bold&gt;In the last 12 hours, have you &lt;bold&gt;vomited or thrown up&lt;/bold&gt;?&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;I did not throw up&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1â2 times&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3â4 times&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;5â6 times&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;7 or more times (Please specify number of times)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;&lt;italic&gt;&lt;underline&gt;QUESTION 3&lt;/underline&gt;&lt;/italic&gt;&lt;/bold&gt;In the last 12 hours, &lt;bold&gt;how many &lt;/bold&gt;times have you had &lt;bold&gt;retching or dry heaves &lt;/bold&gt;without bringing anything up?&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;No Time&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1â2 times&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3â4 times&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;5â6 times&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;7 or more (Please specify number of times)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>8428</offset><text>	1	2	3	4	5	 	QUESTION 1In the last 12 hours, how long have you felt nauseated or sick at your stomach?	Not at all	1 hour or less	2â3 hours	4â6 hours	More than 6 hours (Please specify number of hours)	 	QUESTION 2In the last 12 hours, have you vomited or thrown up?	I did not throw up	1â2 times	3â4 times	5â6 times	7 or more times (Please specify number of times)	 	QUESTION 3In the last 12 hours, how many times have you had retching or dry heaves without bringing anything up?	No Time	1â2 times	3â4 times	5â6 times	7 or more (Please specify number of times)	 	</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9006</offset><text>Before starting the study, a pilot sample of 10 adult volunteers was tested for the feasibility of completing the diary. They took PregVitÂ® for one week followed by MaternaÂ® for one week and were asked to fill out the diary. Minor changes were made to the diary based on comments collected during the pilot phase.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9322</offset><text>Sample size and statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9359</offset><text>The primary end point of interest was the mean rate of adverse events in the two study arms, including decreased compliance. The mean compliance based on pill counts and diary reports were compared between the two study arms by paired Student's t test or signed rank test, as appropriate. Other variables such as mean days of experiencing adverse drug event (ADE), nausea, constipation and other ADE, excluding nausea and constipation, (labeled as other), were also compared using the same statistical tests, as appropriate. The incidence of nausea and noncompliance due to constipation were compared between the two groups using chi-square. All statistical tests were performed using SigmastatÂ® statistical software, Version 2.03 (SPSS Inc, Chicago, IL). Subsequently, multilinear regression analysis was conducted to elucidate determinants that affected compliance rate with the study drugs. Determinants of compliance were chosen based on factors showing significant in recent literature.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10352</offset><text>Rates of constipation were the primary end point of interest, as high iron content is known to induce constipation. Sample size of 100 was calculated to show a 33% decrease in rate of constipation (from 30% to 20%) at power of 80% and alpha of 5%.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>10600</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10608</offset><text>A total of 109 patients from NYGH consented to enroll in the study. Of these 109 patients, 37 patients with NVP and 45 Non NVP patients completed both arms of the study, totaling 82 patients (75.2%). Of 100 patients agreed to enroll in the study at the CGOPB (35 NVP and 65 Non NVP), 18 NVP patients and 38 Non NVP patients, for a total of 56 patients, completed the study (56%). Hence, a total of 138 patients completed the study and were included in the data analysis. The mean gestational age at the start was 8 Â± 2 weeks. There was identical gestational age at start in the two arms. The women who dropped out from the study almost entirely due to the fact that they did not return for follow-up or did not fill out diaries on returning the pill bottles. They did not differ from those who completed the study in any characteristic collected and reported by us. Among those who did not complete the study, there was no higher prevalence to any of the two arms (e.g., PregVitÂ® vs MaternaÂ®).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11605</offset><text>There was a significantly higher incidence of reported constipation, as well as average duration of constipation when taking MaternaÂ® as compared to PregVitÂ® (Table 3).</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>11776</offset><text>Overall study results, comparing PregvitÂ® (low iron) to MaternaÂ® (high iron) over a month administration in a cross-over design.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;(n)&lt;/bold&gt;*&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;PregVit&lt;sup&gt;Â® &lt;/sup&gt;(SD)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Materna&lt;sup&gt;Â® &lt;/sup&gt;(SD)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;p value&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Pill Count (% of 100%)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;78&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;87.7 Â± 20&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;90.9 Â± 17&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.11&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Reported Compliance (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;138&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;90.4 Â± 18&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;92.4 Â± 15&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.42&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Adverse events (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;138&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;17.6 Â± .24&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;20.3 Â± 24&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.14&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Nausea (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;138&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;9.3 Â± 19&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;10.1 Â± 18&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.71&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Constipation time length (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;138&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3.1 Â± 8&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;4.7 Â± 11&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0.05&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Other adverse events&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;138 &lt;bold&gt;(n)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;10.4 Â± 21&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;99.9 Â± 20&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.95&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Nausea rate (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;138&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;41.3 (57/81)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;45.7 (63/75)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.54&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Constipation Rate (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;138&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;22.5% (31/107)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;34.8% (48/90)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;0.03&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>11907</offset><text>	(n)*	PregVitÂ® (SD)	MaternaÂ® (SD)	p value	 	Pill Count (% of 100%)	78	87.7 Â± 20	90.9 Â± 17	0.11	 	Reported Compliance (%)	138	90.4 Â± 18	92.4 Â± 15	0.42	 	Adverse events (%)	138	17.6 Â± .24	20.3 Â± 24	0.14	 	Nausea (%)	138	9.3 Â± 19	10.1 Â± 18	0.71	 	Constipation time length (%)	138	3.1 Â± 8	4.7 Â± 11	0.05	 	Other adverse events	138 (n)	10.4 Â± 21	99.9 Â± 20	0.95	 	Nausea rate (%)	138	41.3 (57/81)	45.7 (63/75)	0.54	 	Constipation Rate (%)	138	22.5% (31/107)	34.8% (48/90)	0.03	 	</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>12394</offset><text>n represents the number of patients (out of 138) who completed any particular item.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12478</offset><text>Multivariate linear regression was conducted to elucidate factors that independently affected compliance. The factors tested included: age, education, province, marital status, weight, NVP severity, any substance used such as illicit drugs and multivitamin supplement (which multivitamin they started the trial with). These factors have been shown in previous studies to affect compliance. The dependent variable used was reported compliance. Including all 138 patients, using both arms of the study, no variable significantly predicted compliance rate (Table 4).</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>13042</offset><text>Multiple linear regression of factors affecting compliance in both treatment arms.</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Independent Variable&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Coefficient&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Standard Error&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;p value&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Age&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.00&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.002&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.43&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Education&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;-0.01&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.011&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Province&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.04&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.026&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Marital Status&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;-0.02&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.028&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.43&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Weight&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.00&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.000&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.14&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;NVP Severity&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;-0.02&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.012&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.08&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Substance use*&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.00&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.036&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.79&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Multivitamin Supplement&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;-0.01&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.019&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.75&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13125</offset><text>Independent Variable	Coefficient	Standard Error	p value	 	Age	0.00	0.002	0.43	 	Education	-0.01	0.011	0.58	 	Province	0.04	0.026	0.17	 	Marital Status	-0.02	0.028	0.43	 	Weight	0.00	0.000	0.14	 	NVP Severity	-0.02	0.012	0.08	 	Substance use*	0.00	0.036	0.79	 	Multivitamin Supplement	-0.01	0.019	0.75	 	</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>13429</offset><text>* alcohol, tobacco or illicit drugs</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13465</offset><text>Finally, multiple linear regression with patients and their reported compliance while taking MaternaÂ® revealed that marital status and NVP severity predicted their reported compliance; single motherhood predicted higher compliance rates whereas more severe NVP predicted a lower compliance rate (Table 5). No such correlation was detected for PregVitÂ®.</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>13820</offset><text>Multiple linear regression of compliance in patients while taking MaternaÂ®</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Independent Variable&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Coefficient&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;Standard Error&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;p value&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Age&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.00&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.002&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.73&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Education&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;-0.02&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.014&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.09&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Province&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.03&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.031&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.37&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Race&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.02&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.010&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.11&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Marital Status&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;-0.08&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.034&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Weight&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.00&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.000&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.14&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;NVP Severity*&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;-0.05&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.014&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Substance**&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;-0.06&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.044&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;0.20&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13896</offset><text>Independent Variable	Coefficient	Standard Error	p value	 	Age	0.00	0.002	0.73	 	Education	-0.02	0.014	0.09	 	Province	0.03	0.031	0.37	 	Race	0.02	0.010	0.11	 	Marital Status	-0.08	0.034	0.02	 	Weight	0.00	0.000	0.14	 	NVP Severity*	-0.05	0.014	0.002	 	Substance**	-0.06	0.044	0.20	 	</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>14180</offset><text>* More severe NVP was associated with significantly lower compliance. No such effect was found with PregvitÂ®, which is a substantially smaller tablet, containing much lower iron content.</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>14368</offset><text>** alcohol, tobacco or illicit drugs</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>14405</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>14416</offset><text>The results of this study demonstrate that pregnant women may experience less constipation when taking PregVitÂ®. These results are likely attributed to the lower iron dose contained in PregVitÂ® relative to MaternaÂ® (35 mg and 60 mg, respectively) (Table 1). The other differences in micronutrient content between the two preparations are not known to affect constipation rate. It should be noted that since the completion of this study the dose of iron in MaternaÂ® has been reduced to 27 mg. The reformulated MaternaÂ® has the same levels of calcium, manganese and zinc as before. Thus, with lower vitamin C content than PregVitÂ®, it is possible that the systemic absorption of iron of MaternaÂ® may be subtherapeutic14. Moreover, studies have suggested an antagonistic relationship between iron and zinc and manganese, in which zinc and manganese reduce the positive effects of iron supplementation and vice versa.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>15337</offset><text>It is likely that the higher dose of zinc, found in MaternaÂ® versus PregVitÂ® plus manganese, (which is not included in PregVitÂ®) all interfere with the absorption of iron. A 1993 study(16) found that supplementation with a low daily dose (18 mg) of iron given in a prenatal supplement together with inhibitive minerals was not sufficient to cover the iron needs of most pregnant women. Importantly, many prenatal supplements currently available still contain 50â60 mg of elemental iron.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>15829</offset><text>Two methods were used to estimate compliance: Patients' reported compliance and pill count. Using these measures, compliance was found to be similar for both products. The similar compliance may be a reflection of better tolerability with PregVitÂ®, being partially offset by the need to take this supplement twice daily, as compared to once daily with MaternaÂ®.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16193</offset><text>Of potential clinical importance, the multivariate analysis revealed that compliance with MaternaÂ® was negatively related to the severity of nausea and vomiting of pregnancy. This agrees with a recent study documenting that the severity of morning sickness adversely affects use of MaternaÂ® (6). This may be explained also by a substantially larger pill size as compared to PregVitÂ®, in addition to the direct effect of iron. These findings suggest that PregVitÂ® may confer an advantage to women suffering from NVP due to both higher tolerability because of lower iron content and a smaller tablet size. Because NVP can very from slight food aversion to hyperemesis gravidarum, we used a validated tool that quantifies the severity of NVP (Table 2).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16947</offset><text>Potential weaknesses of this study are that the participation in this cross over protocol may act to improve compliance among participant, and that, similar to other randomized controlled studies, the demonstrated high compliance figures do not reflect those of naturalistic &quot;real life&quot; drug administration. We experienced a relatively high drop out rate. This did not reflect failure to take the two products but rather lack of motivation of healthy pregnant women to participate in this type of intensive protocol including daily diaries and returning pills. However, because each woman served as her own control, the attrition does not bias the results. The women who dropped out were not different in their characteristics from those who completed the protocol. Importantly, because compliance rate was an important endpoint we refrained from contacting the women to remind them of their participation, an act that could artificially affect compliance, with the medications. Previous studies also reported on diarrhea occurring with micronutrients, however, in our study the occurrence of diarrhea was very rare and not different between the two study interventions.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18118</offset><text>Yet, this study, comparing tolerability and compliance rates between two prenatal micronutrient supplements different in their iron content and administration schedule, has identified several determinants of potential clinical significance, which may affect pregnant women's adherence to micronutrient supplementation.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18437</offset><text>A major problem in primary prevention of congenital anomalies by folic acid or folic acid containing micronutrients is the need to commence supplementation preconceptionally. There is a serious and urgent need to educate potential parents to start such supplementation before pregnancy is confirmed.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>18737</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>18748</offset><text>PregVitÂ®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates. High iron content in multivitamin supplements is associated with adverse effects in pregnancy.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>19016</offset><text>Competing interests</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>19036</offset><text>G. Koren has been a paid consultant for Duchesnay Inc. All other authors declare they have no competing interests'.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>19152</offset><text>Authors' contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>19175</offset><text>Eric Ahn collected all data in Toronto, analyzed the data and wrote the draft manuscript.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>19265</offset><text>Nicholas Pairaudeau oversaw the study in the Toronto site.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>19324</offset><text>Nicholas Pairaudeau Jr. participated in collection and analysis of data.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>19397</offset><text>Yves Cerat, B. Couturier, A. Fortier and E. Paradis oversaw patients and collected the data in the Quebec Site.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>19509</offset><text>Gideon Koren wrote the protocol and oversaw all stages of collection, analysis and writing.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>19601</offset><text>Pre-publication history</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>19625</offset><text>The pre-publication history for this paper can be accessed here:</text></passage><passage><infon key="section_type">REF</infon><infon key="source">Subcommittee on the Tenth Edition of the RDAs. Recommended dietary allowances/Subcommittee on the Tenth Edition of the RDAs, Food and Nutrition Board, Commission on Life Sciences, National Research Council</infon><infon key="type">ref</infon><infon key="year">1989</infon><offset>19690</offset></passage><passage><infon key="fpage">770</infon><infon key="lpage">73</infon><infon key="section_type">REF</infon><infon key="source">Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</infon><infon key="type">ref</infon><infon key="year">2002</infon><offset>19691</offset></passage><passage><infon key="fpage">1832</infon><infon key="lpage">35</infon><infon key="name_0">surname:Czeizel;given-names:AE</infon><infon key="name_1">surname:Dudas;given-names:I</infon><infon key="pub-id_pmid">1307234</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">327</infon><infon key="year">1992</infon><offset>19692</offset><text>Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation</text></passage><passage><infon key="fpage">605</infon><infon key="name_0">surname:Wald;given-names:N</infon><infon key="name_1">surname:Hack Shaw;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">350</infon><infon key="year">1992</infon><offset>19794</offset><text>Folic acid and prevention of neural-tube defects</text></passage><passage><infon key="fpage">12</infon><infon key="lpage">21</infon><infon key="name_0">surname:Botto;given-names:LD</infon><infon key="name_1">surname:Olney;given-names:RS</infon><infon key="name_2">surname:Erickson;given-names:JD</infon><infon key="pub-id_doi">10.1002/ajmg.c.30004</infon><infon key="section_type">REF</infon><infon key="source">Am J Med Genet</infon><infon key="type">ref</infon><infon key="volume">125C</infon><infon key="year">2004</infon><offset>19843</offset><text>Vitamin supplements and the risk for congenital anomalies other than neural tube defects</text></passage><passage><infon key="fpage">12</infon><infon key="lpage">21</infon><infon key="name_0">surname:Botto;given-names:LD</infon><infon key="name_1">surname:Olney;given-names:RS</infon><infon key="name_2">surname:Erickson;given-names:JD</infon><infon key="pub-id_doi">10.1002/ajmg.c.30004</infon><infon key="pub-id_pmid">14755429</infon><infon key="section_type">REF</infon><infon key="source">Am J Med Genet C Semin Med Genet</infon><infon key="type">ref</infon><infon key="volume">125</infon><infon key="year">2004</infon><offset>19932</offset><text>Vitamin supplements and the risk for congenital anomalies other than neural tube defects</text></passage><passage><infon key="name_0">surname:Koren;given-names:G</infon><infon key="name_1">surname:Piwko;given-names:C</infon><infon key="name_2">surname:Ahn;given-names:E</infon><infon key="name_3">surname:Boskovic;given-names:R</infon><infon key="section_type">REF</infon><infon key="source">J Obstet Gynecol</infon><infon key="type">ref</infon><offset>20021</offset><text>Validation studies of the pregnancy unique quantification of emesis (PUQE) scores</text></passage><passage><infon key="fpage">46</infon><infon key="lpage">51</infon><infon key="name_0">surname:Bendich;given-names:A</infon><infon key="pub-id_doi">10.1016/S0899-9007(00)00482-2</infon><infon key="section_type">REF</infon><infon key="source">Nutr</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2001</infon><offset>20103</offset><text>Calcium supplementation and iron status offemales</text></passage><passage><infon key="fpage">106</infon><infon key="lpage">11</infon><infon key="name_0">surname:Cook;given-names:JD</infon><infon key="name_1">surname:Dassenko;given-names:SA</infon><infon key="name_2">surname:Whittaker;given-names:P</infon><infon key="pub-id_pmid">1984334</infon><infon key="section_type">REF</infon><infon key="source">Am J Clin Nutr</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">1991</infon><offset>20153</offset><text>Calcium supplementation: effect on iron absorption</text></passage><passage><infon key="fpage">371</infon><infon key="lpage">98</infon><infon key="name_0">surname:Zijp;given-names:IM</infon><infon key="name_1">surname:Korver;given-names:O</infon><infon key="name_2">surname:Tijburg;given-names:LB</infon><infon key="pub-id_doi">10.1080/10408690091189194</infon><infon key="pub-id_pmid">11029010</infon><infon key="section_type">REF</infon><infon key="source">Crit Rev Food Sci Nutr</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2000</infon><offset>20204</offset><text>Effect of tea and other dietary factors on iron absorption</text></passage><passage><infon key="fpage">257S</infon><infon key="lpage">64S</infon><infon key="name_0">surname:Bothwell;given-names:TH</infon><infon key="pub-id_pmid">10871591</infon><infon key="section_type">REF</infon><infon key="source">Am J Clin Nutr</infon><infon key="type">ref</infon><infon key="volume">72</infon><infon key="year">2000</infon><offset>20263</offset><text>Iron requirements in pregnancy and strategies to meet them</text></passage><passage><infon key="fpage">809</infon><infon key="lpage">815</infon><infon key="name_0">surname:Ahn;given-names:E</infon><infon key="name_1">surname:Kapur;given-names:B</infon><infon key="name_2">surname:Koren;given-names:G</infon><infon key="section_type">REF</infon><infon key="source">J Soc Obst Gynecol Can</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2004</infon><offset>20322</offset><text>Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium</text></passage><passage><infon key="fpage">228</infon><infon key="lpage">31</infon><infon key="name_0">surname:Koren;given-names:G</infon><infon key="name_1">surname:Boscovic;given-names:R</infon><infon key="name_2">surname:Hard;given-names:M</infon><infon key="name_3">surname:Maltepe;given-names:C</infon><infon key="name_4">surname:Navioz;given-names:Y</infon><infon key="name_5">surname:Einarson;given-names:A</infon><infon key="pub-id_doi">10.1067/mob.2002.123054</infon><infon key="section_type">REF</infon><infon key="source">Am J Obstetr Gynecol</infon><infon key="type">ref</infon><infon key="volume">186</infon><infon key="year">2002</infon><offset>20425</offset><text>Motherisk â PUQE scoring system for nausea and vomiting of pregnancy</text></passage><passage><infon key="fpage">513</infon><infon key="lpage">7</infon><infon key="name_0">surname:Leopold;given-names:NA</infon><infon key="name_1">surname:Plansky;given-names:M</infon><infon key="name_2">surname:Hurka;given-names:MR</infon><infon key="pub-id_doi">10.1002/mds.20041</infon><infon key="section_type">REF</infon><infon key="source">Mar Disord</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2004</infon><offset>20496</offset><text>Drug adherence in Parkinson's disease</text></passage><passage><infon key="fpage">120</infon><infon key="lpage">1</infon><infon key="name_0">surname:Yavuz;given-names:A</infon><infon key="name_1">surname:Tuncer;given-names:M</infon><infon key="name_2">surname:Erdogran;given-names:O</infon><infon key="name_3">surname:Gurkan;given-names:A</infon><infon key="name_4">surname:Cetinkaya;given-names:R</infon><infon key="name_5">surname:Akbas;given-names:SH</infon><infon key="pub-id_doi">10.1016/j.transproceed.2003.11.052</infon><infon key="pub-id_pmid">15013319</infon><infon key="section_type">REF</infon><infon key="source">Transplant Proc</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2004</infon><offset>20534</offset><text>Is there any effect of compliance on clinical parameters of renal transplant recipients?</text></passage><passage><infon key="fpage">16</infon><infon key="lpage">23</infon><infon key="name_0">surname:Reimherr;given-names:FW</infon><infon key="name_1">surname:Strong;given-names:RE</infon><infon key="name_2">surname:Merchant;given-names:BK</infon><infon key="name_3">surname:Hedges;given-names:DW</infon><infon key="name_4">surname:Wender;given-names:PH</infon><infon key="pub-id_pmid">11599643</infon><infon key="section_type">REF</infon><infon key="source">J Clin Psychiatry</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2001</infon><offset>20623</offset><text>Factors affecting return of symptoms 1 year after treatment in major depression</text></passage><passage><infon key="fpage">1212</infon><infon key="lpage">9</infon><infon key="name_0">surname:Smetana;given-names:GW</infon><infon key="name_1">surname:Davis;given-names:RB</infon><infon key="name_2">surname:Phillis;given-names:RS</infon><infon key="pub-id_doi">10.1111/j.1525-1497.2004.30362.x</infon><infon key="pub-id_pmid">15610332</infon><infon key="section_type">REF</infon><infon key="source">J Gen Intern Med</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2004</infon><offset>20703</offset><text>Factors that influence patient response to requests to change to a unified restrictive formulary</text></passage><passage><infon key="fpage">65</infon><infon key="lpage">77</infon><infon key="name_0">surname:Ekenved;given-names:G</infon><infon key="name_1">surname:Halvorsen;given-names:L</infon><infon key="name_2">surname:Solvell;given-names:L</infon><infon key="pub-id_pmid">1064903</infon><infon key="section_type">REF</infon><infon key="source">Scand J Haematol Suppl</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">1976</infon><offset>20800</offset><text>Influence of a liquid antacid on the absorption of different iron salts</text></passage><passage><infon key="fpage">141</infon><infon key="lpage">4</infon><infon key="name_0">surname:Crofton;given-names:RW</infon><infon key="name_1">surname:Gvozdanovic;given-names:D</infon><infon key="name_2">surname:Gvozdanovic;given-names:S</infon><infon key="name_3">surname:Khin;given-names:CC</infon><infon key="name_4">surname:Brunt;given-names:PW</infon><infon key="name_5">surname:Mowat;given-names:NA</infon><infon key="name_6">surname:Aggett;given-names:PJ</infon><infon key="pub-id_pmid">2502004</infon><infon key="section_type">REF</infon><infon key="source">Am J Clin Nutr</infon><infon key="type">ref</infon><infon key="volume">50</infon><infon key="year">1989</infon><offset>20872</offset><text>Inorganic zinc and the intestinal absorption offerrous iron</text></passage><passage><infon key="fpage">152</infon><infon key="lpage">6</infon><infon key="name_0">surname:Rossander-Hulten;given-names:L</infon><infon key="name_1">surname:Brune;given-names:M</infon><infon key="name_2">surname:Sandstrom;given-names:B</infon><infon key="name_3">surname:Lonnerdal;given-names:B</infon><infon key="name_4">surname:Hallberg;given-names:L</infon><infon key="pub-id_pmid">2058577</infon><infon key="section_type">REF</infon><infon key="source">Am J Clin Nutr</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">1991</infon><offset>20932</offset><text>Competitive inhibition of iron absorption by manganese and zinc in humans</text></passage><passage><infon key="fpage">93</infon><infon key="lpage">8</infon><infon key="name_0">surname:Thomsen;given-names:JK</infon><infon key="name_1">surname:Prien-Larsen;given-names:JC</infon><infon key="name_2">surname:Devantier;given-names:A</infon><infon key="name_3">surname:Fogh-Andersen;given-names:N</infon><infon key="pub-id_pmid">8383415</infon><infon key="section_type">REF</infon><infon key="source">Acta Obstet Gynecol Scand</infon><infon key="type">ref</infon><infon key="volume">72</infon><infon key="year">1993</infon><offset>21006</offset><text>Low dose iron supplementation does not cover the need for iron during pregnancy</text></passage></document></collection>
